Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

114results about How to "Prevention and therapy" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Device and method for intra-bronchial provision of a therapeutic agent

InactiveUS6929637B2Inhibit movementLimit transportBronchiPharmaceutical delivery mechanismDuring expirationExhalation

The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Device and method for intra-bronchial provision of a therapeutic agent

Device and method for intra-bronchial provision of a therapeutic agent

Device and method for intra-bronchial provision of a therapeutic agent

Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)

Cardiac arrhythmia detector using ECG waveform-factor and its irregularity

InactiveUS6480734B1Avoiding unnecessary shockSignificant energy savingElectrocardiographyHeart defibrillatorsVentricular tachycardiaCardiac monitoring

A cardiac monitor is provided that monitors the condition of the heart of a cardiac patient and generates signals indicating one of several conditions, such as supraventricular tachycardia, ventricular tachycardia and ventricular fibrillation. In order to generate these signals, the ECG from the patient is analyzed to determine a cardiac interval and heart rate, as well as a waveform factor and a waveform factor irregularity. The waveform factor is derived from the average of the ECG amplitudes during a cardiac interval and the peak value of the ECG during the same interval. Preferably, a running average is calculated over several intervals. This waveform factor is then used to detect shockable ventricular arrhythmia. The waveform factor irregularity is indicative of the variability of the waveform factor and is used to differentiate between ventricular tachycardia and ventricular defibrillation.

Cardiac arrhythmia detector using ECG waveform-factor and its irregularity

Cardiac arrhythmia detector using ECG waveform-factor and its irregularity

Cardiac arrhythmia detector using ECG waveform-factor and its irregularity

Owner:ZOLL MEDICAL CORPORATION

Medical device for vessel compatibility during high pressure infusion

InactiveUS20080039786A1Increase pressureLimiting contactStentsBalloon catheterShear stressSlurry

The invention provides devices that can be used to deliver a therapeutic agent to a treatment site within the vessel of a patient at increased pressure, while limiting the contact with and pressure placed on the vessel walls. Devices according to the invention include an expandable structure arranged around and on a tube having a lumen. The expandable structure may include a sealing ring that makes contact with the interior surface of a vessel to prevent or decrease fluid flow during delivery of a therapeutic agent. This allows delivery of a therapeutic agent with decreased risk of injury to the treatment site. The invention also provides for large lumen diameters, preventing shearing stress on therapeutic agents such as cell slurries.

Medical device for vessel compatibility during high pressure infusion

Medical device for vessel compatibility during high pressure infusion

Medical device for vessel compatibility during high pressure infusion

Owner:BOSTON SCI SCIMED INC

Control Systems and Methods for Blood or Fluid Handling Medical Devices

ActiveUS20160058933A1Prevention and therapyPrevent initiationMechanical/radiation/invasive therapiesOther blood circulation devicesMalwareControl software

A processor of a medical device configured to communicate with a remote server can be programmed to protect the medical device from exposure to unauthorized or malicious software. A system or method to implement this form of protection can include, for example, at least one processor on the medical device, a control software module that controls the operation of the medical device and is executable on the processor, a data management module that manages data flow to and from the control software module from sources external to the medical device, and an agent module that has access to a limited number of designated memory locations in the medical device. In addition, a hemodialysis apparatus can be configured to operate in conjunction with an apparatus for providing purified water from a source such as a municipal water supply or a well. A system for controlling delivery of purified water to the hemodialysis apparatus can comprise a therapy controller of the hemodialysis apparatus configured to communicate with a controller of a water purification device, and a user interface controller of the hemodialysis apparatus configured to communicate with the therapy controller, and to send data to and receive data from a user interface.

Control Systems and Methods for Blood or Fluid Handling Medical Devices

Control Systems and Methods for Blood or Fluid Handling Medical Devices

Control Systems and Methods for Blood or Fluid Handling Medical Devices

Owner:DEKA PROD LLP

Anti-Cd14 Antibody Fusion Protein

InactiveUS20080286290A1Prevention and therapyGuaranteed stable actionAntibacterial agentsBiocideProteinase activityCD14

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Anti-Cd14 Antibody Fusion Protein

Anti-Cd14 Antibody Fusion Protein

Anti-Cd14 Antibody Fusion Protein

Owner:MOCHIDA PHARM CO LTD

Chemokine receptor antagonists and use thereof

InactiveUS8168783B2Prevention and therapyBiocideSenses disorderArterial Occlusive DiseasesMental nerve

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac / vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

Chemokine receptor antagonists and use thereof

Chemokine receptor antagonists and use thereof

Chemokine receptor antagonists and use thereof

Owner:ONO PHARMA CO LTD

Gene expression signature for prediction of human cancer progression

InactiveUS20060183141A1Increase probabilityOptimize choiceSugar derivativesMicrobiological testing/measurementHuman cancerLymphatic Spread

Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.

Gene expression signature for prediction of human cancer progression

Gene expression signature for prediction of human cancer progression

Gene expression signature for prediction of human cancer progression

Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

ActiveUS20060035882A1Reduce usageLess side effectsBiocideNervous disorderNeuralgiaDisease cause

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

Owner:JAPAN TOBACCO INC

4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors

InactiveUS20070105859A1Enhanced inhibitory effectExcellent stability in solubilityAntibacterial agentsBiocideMitogen activate proteinPharmaceutical medicine

A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below:

wherein, R¹, R², R³, R⁴, R⁵, R⁶, Q, R⁸, and R⁹have the same meanings as R¹, R², R³, R⁴, R⁵, R⁶, Q, R⁸, and R⁹in the specification.

4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors

4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors

4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors

Owner:CHUGAI PHARMA CO LTD

Apheresis, administration of agent, or combination thereof

InactiveUS20110033463A1Peripheral side effect be reduceAugment therapyOrganic active ingredientsNervous disorderΓ secretaseAntioxidant

A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation.

Apheresis, administration of agent, or combination thereof

Apheresis, administration of agent, or combination thereof

Apheresis, administration of agent, or combination thereof

Owner:MEDTRONIC INC

Compound having acidic group which may be protected, and use thereof

InactiveUS20090192182A1Prevention and therapyBiocideSenses disorderMental nerveArthritis

A compound represented by general formula (I):

a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Compound having acidic group which may be protected, and use thereof

Compound having acidic group which may be protected, and use thereof

Compound having acidic group which may be protected, and use thereof

Owner:ONO PHARMA CO LTD

Novel Anti-Plgf A Antibody

InactiveUS20080193455A1Slow tumor growthInhibit P1GFSenses disorderAntipyreticA AntibodyPathological Angiogenesis

The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.

Novel Anti-Plgf A Antibody

Novel Anti-Plgf A Antibody

Novel Anti-Plgf A Antibody

Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2

Apheresis of a target molecule from cerebrospinal fluid

InactiveUS20100030196A1Prevention and therapyBlock deliveryWound drainsDialysis systemsAntibodyCatheter device

A system includes (i) a medium having a solid support to which an antibody directed to target molecule is bound, (ii) a reservoir for containing the medium, (iii) a first catheter, and (iv) a second catheter. The first catheter has a proximal end portion, an opening for removal of cerebrospinal fluid from a subject, and a lumen extending from the proximal end portion to the opening. The first catheter is operably couplable to the reservoir such that fluid is capable of flowing from the lumen to the reservoir. The second catheter has a proximal end portion, a delivery region for returning cerebrospinal fluid to the subject, and a lumen extending from the proximal end portion to the delivery region. The second catheter is operably couplable to the reservoir such that fluid is capable of flowing from the reservoir to the lumen.

Apheresis of a target molecule from cerebrospinal fluid

Apheresis of a target molecule from cerebrospinal fluid

Apheresis of a target molecule from cerebrospinal fluid

Owner:MEDTRONIC INC

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

InactiveUS20060035939A1Reduce usageLess side effectsBiocideSenses disorderDiseaseDepressant

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R¹is a C1-6 alkyl group which may be substituted, R²is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R³is a hydrogen atom or a C1-6 alkyl group, R⁴is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

Owner:JAPAN TOBACCO INC

Compound containing basic group and use thereof

InactiveUS7951816B2Prevention and therapyBiocideSenses disorderMental nerveCancer metastasis

The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Compound containing basic group and use thereof

Compound containing basic group and use thereof

Compound containing basic group and use thereof

Owner:ONO PHARMA CO LTD

Pyrrolopyridazine derivatives

InactiveUS6063782APrevention and therapyStrong inhibitory activityBiocideOrganic chemistryArylHydrogen atom

Pyrrolopyridazine derivatives having the general formula. In the above formula, R1 represents a C2-C6alkenyl-group, a halogeno-C2-C6-alkenyl group, a C6-C10 aryl-C2-C6-alkenyl group, a C2-C6 alkynyl group, a C3-C7 cycloalkyl group, a C3-C7 cycloalkyl-C1-C6-alkyl group, a C5-C7 cycloalkenyl-C1-C6-alkyl group or a halogeno-C1-C6-alkyl group; R2 and R3 are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C6-C10 aryl group; R4 represents a hydrogen atom or a C1-C6 alkyl group; R5 represents a C6-C10 aryl group or a 5-10 membered heteroaryl group comtaining heteroatom(s) selected from nitrogen, oxygen and sulfur;

Owner:SANKYO CO LTD +1

Hydrazone derivative

InactiveUS20060276433A1Conveniently accumulationInhibit bindingBiocideNervous disorderArylHydrazone

A compound represented by the following formula (I):

wherein R¹represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R²represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R³represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof.

Hydrazone derivative

Hydrazone derivative

Hydrazone derivative

Owner:DAIICHI PHARMA CO LTD

Compound Containing Basic Group and Use Thereof

InactiveUS20080009495A1Less effectPrevention and therapyBiocideSenses disorderSolventCompound (substance)

The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Compound Containing Basic Group and Use Thereof

Compound Containing Basic Group and Use Thereof

Compound Containing Basic Group and Use Thereof

Owner:ONO PHARMA

Device and method for intra-bronchial provision of a therapeutic agent

InactiveUS20060074382A1Prevent over-inflationPrevention and therapyBronchiTracheaeIntensive care medicineMembrane configuration

The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.

Device and method for intra-bronchial provision of a therapeutic agent

Device and method for intra-bronchial provision of a therapeutic agent

Device and method for intra-bronchial provision of a therapeutic agent

Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

InactiveUS20070149517A1Effective in medical treatmentEffective preventionOrganic active ingredientsNervous disorderDiseaseAlkoxy group

A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR³; R¹is a hydrogen atom or a halogen atom; R²is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R³is a halogen atom. However, R¹is a halogen atom when X is CR³). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

Owner:JAPAN TOBACCO INC

Basic group-containing compound and use thereof

InactiveUS20090169567A1Prevention and therapyBiocideSenses disorderMental nerveVascular problem

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac / vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

Basic group-containing compound and use thereof

Basic group-containing compound and use thereof

Basic group-containing compound and use thereof

Owner:ONO PHARMA

Substituted polycyclic carbamoylpyridone derivative

ActiveUS20120184734A1Prevention and therapyOrganic chemistryAntiviralsMedicineAcyl group

This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.

Substituted polycyclic carbamoylpyridone derivative

Substituted polycyclic carbamoylpyridone derivative

Substituted polycyclic carbamoylpyridone derivative

Owner:SHIONOGI & CO LTD

Anti-CD14 antibody fusion protein

InactiveUS8252905B2Guaranteed stable actionPrevention and therapyAntibacterial agentsBiocideProteinase activityCD14

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Anti-CD14 antibody fusion protein

Anti-CD14 antibody fusion protein

Anti-CD14 antibody fusion protein

Owner:MOCHIDA PHARM CO LTD

Therapeutic agent for pruritus

ActiveUS20100310556A1Treating and preventing pruritusPrevention and therapyPeptide/protein ingredientsAntibody ingredientsPrurigoBacteriophage

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

Therapeutic agent for pruritus

Therapeutic agent for pruritus

Therapeutic agent for pruritus

Owner:CHUGAI PHARMA CO LTD

Compound containing basic group and use thereof

InactiveUS20110142856A1Prevention and therapyBiocideSenses disorderMental nerveCancer metastasis

The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof.The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoidarthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Compound containing basic group and use thereof

Compound containing basic group and use thereof

Compound containing basic group and use thereof

Owner:ONO PHARMA CO LTD

Tricyclic Compound And Use Thereof

ActiveUS20080114012A1Promote oral absorptionHigh affinityBiocideNervous disorderAnti stressMedicinal chemistry

The present invention relates to the compound represented by formula (I):

(wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof.

Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.

Tricyclic Compound And Use Thereof

Tricyclic Compound And Use Thereof

Tricyclic Compound And Use Thereof

Owner:ONO PHARMA CO LTD

Therapeutic composition, and use of a cell-free substance

InactiveUS20100104641A1Efficient preparationHighly efficient mannerBiocidePowder deliveryCell freeMedicine

The invention relates to a therapeutic composition, a method for producing a therapeutic composition, and the use of a cell-free substance, especially a cell-free bone or cartilage matrix. The disclosed therapeutic composition comprises at least a cell-free substance obtained from stimulated stem cells and / or precursor cells. Immunogenic reactions during in vivo therapeutic use are prevented by the fact that the therapeutic composition is free from cells and contains no typically antigenic cell components. The disclosed composition can therefore be universally used for the therapeutic purposes regardless of the origin of the stem cells and / or precursor cells and utilize the natural regenerative potency thereof in a highly efficient manner for replacing tissue, e.g. for a suitable bone and / or cartilage structure.

Therapeutic composition, and use of a cell-free substance

Therapeutic composition, and use of a cell-free substance

Therapeutic composition, and use of a cell-free substance

Owner:STIFTUNG CAESAR +1

17BetaHSD TYPE 5 INHIBITOR

InactiveUS20090181960A1Suppress synthesisSuppress intracrine androgen synthesisBiocideOrganic chemistrySelective inhibitionBenign prostatic hyperplasia (BPH)

To provide a novel and excellent method for treating and / or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5.It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and / or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

17BetaHSD TYPE 5 INHIBITOR

17BetaHSD TYPE 5 INHIBITOR

17BetaHSD TYPE 5 INHIBITOR

Owner:ASTELLAS PHARMA INC

Detection of mycobacteria

InactiveUS6383763B1Rapid assessmentLess sensitiveAntibody ingredientsBiological testingMicrobiologyGenus

The present invention is directed to methods and compositions for the detection of infection and disease due to members of the genus Mycobacterium. In particular, the present invention is well-suited to the detection and identification of patients with disease or infection due to M. tuberculosis or MAC.

Detection of mycobacteria

Detection of mycobacteria

Detection of mycobacteria

Owner:CASE WESTERN RESERVE UNIV

Substituted polycyclic pyridone derivatives and prodrugs thereof

ActiveUS20180118760A1Inhibitory activityPrevention and therapyGroup 4/14 element organic compoundsPowder deliveryHalogenHydrogen

The present invention provides the following compounds having anti-viral activity.

A¹is CR^1AR^1B, S or O;
A²is CR^2AR^2B, S or O;
A³is CR^3AR^3B, S or O;
A⁴is CR^4AR^4B, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A¹, A², A³, A⁴, nitrogen atom adjacent to A¹and carbon atom adjacent to A¹, is 1 or 2;
R^1Aand R^1Bare each independently hydrogen, halogen, alkyl, or the like;
R^2Aand R^2Bare each independently hydrogen, halogen, alkyl, or the like;
R^3Aand R^3Bare each independently hydrogen, halogen, alkyl, or the like;
R^4Aand R^4Bare each independently hydrogen, halogen, alkyl, or the like;
R^3Aand R^3Bmay be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;
X is CH₂, S or O;
R¹is each independently halogen, hydroxy, or the like;
m is any integer of 0 to 2; and
n is any integer of 1 to 2.

Substituted polycyclic pyridone derivatives and prodrugs thereof

Substituted polycyclic pyridone derivatives and prodrugs thereof

Substituted polycyclic pyridone derivatives and prodrugs thereof

Owner:SHIONOGI & CO LTD

Popular searches

Prevent movement Control flow Airflow limitation Accurate separation Address limitations Receive treatment well Choose accurately Reliable distinction Control pressure Reduce risk

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap